Loading...
01/10 00:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several challenges: declining revenue, increased operating loss, and competitive pressures against EscharEx. Despite some positive developments, such as the new manufacturing facility and improved gross margin, these are overshadowed by financial struggles and supply chain issues. The Q&A session highlighted regulatory uncertainties and management's vague responses about future government purchases and financial projections. Without a share repurchase program or positive shareholder return plan, the overall sentiment is negative, likely leading to a stock price decline of 2% to 8%.
Total Revenue $4 million (down from $5 million in Q1 2024), reflecting lower revenue from BARDA-funded development services as the NexoBrid development program approaches completion.
Gross Profit $0.7 million with a gross margin of 19% (up from $0.6 million and 12% gross margin in Q1 2024), due to a favorable change in revenue mix.
R&D Expenses $2.9 million (up from $1.5 million in Q1 2024), reflecting continued investment in the EscharEx VALUE Phase III trial and associated development activities.
SG&A Expenses $3.1 million (up from $2.9 million in Q1 2024), indicating increased operational costs.
Operating Loss $5.2 million (up from $3.7 million in Q1 2024), reflecting higher expenses.
Net Loss $0.7 million or $0.07 per share (improved from a net loss of $9.7 million or $1.05 per share in Q1 2024), primarily driven by noncash financial income related to warrant revaluation.
Adjusted EBITDA Loss $4 million (up from $2.9 million in Q1 2024), indicating continued operational challenges.
Cash Position $38.7 million (down from $43.6 million at year-end 2024), with $5.1 million used to fund operations during the quarter.
EscharEx: The VALUE Phase III study for EscharEx is on track, with recruitment progressing as planned. The trial will enroll 216 patients across approximately 40 sites in the US and Europe, with results expected to support regulatory submissions and commercial positioning.
NexoBrid: NexoBrid continues to gain global traction, with a 207% year-over-year increase in revenue reported by commercial partner Vericel. Demand exceeds manufacturing capacity, and a new facility is expected to be operational by year-end 2025.
European Innovation Council Grant: The company secured a EUR2.5 million grant to support clinical and regulatory advancement of EscharEx for diabetic foot ulcers.
US Government Interest: The US government has expressed interest in establishing a domestic backup manufacturing site for NexoBrid, supported by BARDA.
Manufacturing Facility: A new manufacturing facility is on track for operational readiness by year-end 2025, significantly expanding production capabilities for NexoBrid.
Collaboration with Kerecis: A collaboration with Kerecis marks a significant milestone, bringing nearly all major wound care companies into MediWound's clinical research program.
Regulatory Issues: The company is planning a 45 patient randomized prospective Phase II head-to-head comparison of EscharEx versus Collagenase, which is scheduled to begin in the second half of 2025. This study is critical for market access and pricing strategies, indicating potential regulatory hurdles.
Supply Chain Challenges: NexoBrid's demand continues to exceed manufacturing capacity, highlighting potential supply chain challenges as the company works to expand production capabilities with a new manufacturing facility expected to be operational by year-end 2025.
Economic Factors: Total revenue for Q1 2025 was $4 million, a decline from $5 million in Q1 2024, attributed to lower revenue from BARDA-funded development services as the NexoBrid development program nears completion, indicating economic pressures affecting revenue streams.
Competitive Pressures: EscharEx is positioned against SANTYL, the only FDA approved enzymatic debridement agent, indicating competitive pressures in the market for wound care products.
Financial Performance: The company reported an operating loss of $5.2 million for Q1 2025, an increase from $3.7 million in Q1 2024, reflecting ongoing financial challenges as they invest in R&D and operational scaling.
EscharEx VALUE Phase III Study: Recruitment is progressing as planned, with 216 patients to be enrolled across 40 sites in the US and Europe. Results expected to support regulatory submissions and commercial positioning.
NexoBrid Manufacturing Expansion: New manufacturing facility operational readiness expected by year-end 2025, with commercial availability anticipated in 2026.
Strategic Collaborations: Collaboration with Kerecis and participation from major wound care companies to support clinical development programs.
Funding for EscharEx: Secured EUR2.5 million grant from the European Innovation Council Accelerator to support clinical and regulatory advancement.
US Manufacturing Site Planning: Initiated planning for a future US-based facility supported by BARDA.
Revenue Expectations: Total revenue for Q1 2025 was $4 million, down from $5 million in Q1 2024.
R&D Expenses: R&D expenses totaled $2.9 million, reflecting continued investment in EscharEx.
Operating Loss: Operating loss for Q1 2025 was $5.2 million, compared to $3.7 million in Q1 2024.
Cash Position: As of March 31, 2025, cash and equivalents were $38.7 million, down from $43.6 million at year-end 2024.
Future Growth Outlook: With a solid foundation and strategic alliances, the company is well positioned for long-term value delivery.
Share Repurchase Program: None
The earnings call summary presents a mixed picture with both positive and negative aspects. The company shows strong partnerships and financial flexibility, but faces challenges like increased EBITDA loss and dependency on government contracts. The Q&A reveals optimism in sales estimates and market strategy but lacks transparency in revenue breakdown and contract timelines. Overall, the sentiment is neutral as positive elements are balanced by uncertainties and financial challenges.
The earnings call presented mixed signals. While strategic collaborations and funding are positive, the decline in revenue and increased operating loss are concerning. The Q&A highlighted ongoing projects and potential future benefits but also revealed some uncertainties, particularly regarding patient recruitment and manufacturing timelines. Despite some positive developments, the overall financial health and lack of immediate catalysts suggest a neutral market reaction.
The earnings call reveals several challenges: declining revenue, increased operating loss, and competitive pressures against EscharEx. Despite some positive developments, such as the new manufacturing facility and improved gross margin, these are overshadowed by financial struggles and supply chain issues. The Q&A session highlighted regulatory uncertainties and management's vague responses about future government purchases and financial projections. Without a share repurchase program or positive shareholder return plan, the overall sentiment is negative, likely leading to a stock price decline of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
